-
Plenary Session 7 tackles radioimmunotherapy and surgery’s role in immunotherapy era
November 27, 2021Plenary Session 7 “Combining immunotherapy with local treatment of GU cancer” covered topics on radioimmunotherapy for bladder preservation and...
01 -
Trial updates: NIMBUS, FLAME and IMvigor130
November 27, 2021Presenters of Plenary Session 5 kickstarted day three of EMUC21 and delivered developments on the trials NIMBUS, Focal Lesion...
-
Plenary Session 3: Promising biomarkers and novel approaches for patients with BCG failure
November 26, 2021Presenter Prof. Paolo Gontero (IT) launched Plenary Session 3 “Bladder cancer: Bladder-preserving strategies in NMIBC” at EMUC21 today with...
-
PSMA PET/CT: Prime tool in staging and treatment monitoring
November 26, 2021Plenary Session 1 “Prostate cancer staging in 2021: Where are we, where are we going?” provided delegates with expert...
-
Expectations for new WHO classification and what’s next in PCa grading
November 25, 2021The EMUC Symposium on Genitourinary Pathology and Molecular Diagnostics (ESUP) delivered updates and expert insights on topics such as...
-
EMUC19 sums up GU cancer reports from APCCC, ESUI19, EAURF and PRIAS
November 15, 2019The “Highlights in GU cancers” session commenced today on day two of 11th European Multidisciplinary Congress on Urological Cancers...
-
HoT courses highlight MRI reading and fusion biopsy
November 15, 2019Two Hands-on Training (HoT) courses organised by the European School of Urology (ESU) and the EAU Section of Urological...
-
Urine biomarkers may detect disease state in NMIBC
October 28, 2019The Scientific Programme of the EMUC congress is well-known for its broad coverage of relevant and current updates on...
-
What to do when faced with a nightmare PCa case
August 6, 2019Imagine a treatment strategy not working on your patient. The situation escalates and the patient suffers from complications. What...
-
EMUC18 addresses current dilemmas in mPCa treatment
November 12, 2018What is the role of cell-free circulating tumour DNA (ctDNA) in the treatment of metastatic prostate cancer (mPCa)? How...
